Iovance Biotherapeutics to Present at Upcoming Conferences

Iovance Biotherapeutics announced that senior leadership will present at the Wells Fargo Healthcare Conference (September 10) and H.C. Wainwright Global Investment Conference (September 15). The company reported record Q2 2026 revenue of approximately $99M, with U.S. Amtagvi revenue reaching ~$91M and 66% year-over-year growth. Gross margin improved to 56%, and the FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas.